Janssen Biologics creates, acquires and markets unique biopharmaceutical therapies. Their innovative products focus on the management of three major disease areas; cardiovascular, immunological disorders and cancer.
They strive to be a prominent company. Not only by the marketing of important new products. They also effectuate to increase the applications of their existing products. This means investing in the right research, forging the right business partnerships and hiring the right people to maintain the highest quality.
Janssen Vaccine Facility (VF), part of the Johnson & Johnson Family of Companies, is a state-of-the-art vaccine manufacturing facility at the Bioscience park in Leiden, where they proudly produce leading medicines against diseases that have a global impact, such as vaccines against HIV and RSV. The vaccine facility is designed to manufacture drug substance on a 1000 L scale for Phase III and commercial phase.
The GMP Department consists of approx. 14 persons who play a central role within the VF to ensure GMP compliance in support of production, product transfers and improvement projects.